Disclosures for Palumbo Antonio, MD
|
|
|
- Dora Ross
- 5 years ago
- Views:
Transcription
1 Disclosures for Palumbo Antonio, MD Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau Honoraria Scientific Advisory Board o relevant conflicts of interest to declare o relevant conflicts of interest to declare Amgen, Bristol-Myers Squibb, Genmab, Celgene, Janssen, Millennium, Onyx o relevant conflicts of interest to declare o relevant conflicts of interest to declare Amgen, Bristol-Myers Squibb, Genmab, Celgene, Janssen, Millennium, Onyx, ovartis, Sanofi o relevant conflicts of interest to declare Presentation includes discussion of the off-label use of a drug or drugs
2 To maintain or not to maintain? IMiDs vs PI Yes: IMiDs Antonio Palumbo University of Torino, Italy
3 MRD sensitivity Serum tools Immunophenotype RQ- PCR EXT-GEERATIO SEQUECE cure
4 Patients (%) PFS: landmark analyses Maintenance vs. placebo MPR Lenalidomide Maintenance VMPT VT Maintenance Off therapy 100 Median PFS HR (p value) MPR-R 26 months 0.34 (< 0.001) year PFS Median PFS HR (p value) VMPT-VT 33% 32 months 0.56 (< ) MPR 7 months /A VMP 16% 19 months /A Improvement: 19 months 50 Improvement: 13 months Time (months) Time (months) Palumbo A, et al. Engl J Med. 2012;366:1759 Palumbo A, et al. J Clin Oncol. 2010;28:5101 M, melphalan; P, prednisone; R, lenalidomide; V, bortezomib; T, thalidomide; PFS, progression-free survival; A, not available
5 72 wks Patients (%) Continuous vs Fixed-Duration: PFS advantage Rd vs Rd18 vs MPT MPR-R vs MPR vs MP VMPT-VT vs VMP Median Median Median Rd 25.5 mos MPR-R 31 mos VMP-VT 35.3 mos Rd mos MPR 14 mos VMP 28.8 mos MPT 21.2 mos MP 13 mos Time (months) Time (months) Time (months) Facon T, et al. Blood. 2013;122:abstract 2. Palumbo A, et al. EJM 2012;366:1759 Palumbo A, et al. JCO 2010;28:5101 MPT, melphalan, prednisolone, thalidomide; Rd, lenalidomide plus low-dose dexamethasone; MPR-R, melphalan-prednisone-lenalidomide and lenalidomide maintenance; MPR; melphalan-prednisone-lenalidomide; MP; melphalan-prednisone; VMPT-VT, bortezomib-melphalan-prednisone-thalidomide and bortezomib-thalidomide maintenance; VMP, bortezomib-melphalan-prednisone; PFS, progression-free survival
6 Thalidomide 1 Continuous vs Fixed-Duration: OS Progression Free Survival Study Maintenance Control Hazard ratio (fixed) 95% CI Hazard ratio (fixed) 95% CI CALGB (0.36, 0.63) MM (0.18, 0.64) IFM (0.39, 0.64) RV-MM-PI (0.40, 0.67) Total (95% CI) (0.41, 0.58) Lenalidomide 2 Bortezomib Favors treatment Favors control Overall Survival Study Progression Free Survival Maintenance Control Hazard ratio (fixed) Hazard ratio (fixed) Study Maintenance Control Hazard ratio 95% CI (fixed) Hazard ratio 95% CI (fixed) 95% CI 95% CI CALGB (0.42, 0.88) MM VMPT-VT 015 vs VMP (0.53, (0.50, 1.18) 0.90) IFM PAD-V vs VAD-T (0.77, (0.62, 1.46) 0.90) RV-MM-PI (0.42, 0.92) Total (95% CI) (0.54, 0.87) Total (95% CI) (0.62, 0.95) Overall Survival Study Maintenance Control Favors treatment Favors treatment Favors control Favors control Hazard ratio (fixed) Hazard ratio (fixed) 95% CI 95% CI VMPT-VT vs VMP (0.55, 0.99) PAD-V vs VAD-T (0.56, 0.96) Total (95% CI) (0.56, 0.99) Favors treatment Favors control 1. Ludwig H, et al. Blood. 2012; 2. McCarthy PL, et al. Engl J Med 2012; Palumbo A, et al. Engl J Med 2012; Attal M, et al. Engl J Med 2012; Palumbo A, et al. ASCO 2013; 3. Sonneveld P, et al. J Clin Oncol 2012; Palumbo A, et al. J Clin Oncol. 2010
7 KRd: Fixed-Duration vs Kd: Continuous ASPIRE: KRd vs Rd Progression-Free Survival ITT Population (=792) EDEAVOR: Kd vs Vd Progression-Free Survival ITT Population (=929) 1.0 Median PFS 1.0 Median PFS 0.8 KRd (=396) Rd (=396) 26.3 mos 17.6 mos 0.8 Kd ( = 464) Vd ( = 465) 18.7 mos 9.4 mos KRd Rd Months HR 0.69 P < Stewart AK, et al. EJM 2015:372:142 KRd, carfilzomib-lenalidomide-dexamethasone; Rd, lenalidomide-dexamethasone; Kd, carfilzomib-dexamethasone; Vd, bortezomibdexamethasone; ITT, intention-to-treat; PFS, progression-free survival 0.2 Kd Vd Months HR 0.53 P < Dimopoulos MA, et al. ASCO 2015; abs 8509
8 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% VT maintenance GIMEMA MM Best response to treatment (n=149) Best response, n (%) All patients, n=149 Overall CR+VGPR+PR 146 (98) CR 81 (54) VGPR 37 (25) PR 28 (19) SD 3 (2) 0% VMPT induction CR VGPR PR SD Overall 17 patients improved their response during VT maintenance: - 5 VGPR improved to CR - 10 PR improved to 8 VGPR and 2 CR - 2 SD improved to 1 PR and 1 CR Palumbo A, et al. J Clin Oncol. 2014; 32:634-40
9 GIMEMA MM Grade 3-4 AEs during VT maintenance neutropenia thrombocytopenia nervous system cardiologic infections vascular metabolic other 0% 1% 2% 3% 4% 5% 6% 7% 8% Patients (%) Palumbo A, et al. J Clin Oncol. 2014; 32:634-40
10 Car-Len maintenance UITO-MM-01/FORTE study IDUCTIO COSOL. MAIT. R A D O M I Z A T I O CCyD (4 28-d cycles) C: 20 mg/m2 IV d 1-2 cycle 1; 36 mg/m2 IV once daily d 8-9,15-16 cycle 1;for all subsequent doses 36 mg/m2 IV once daily d 1-2,8-9,15-16 Cy: 300 mg/m2 PO d 1,8,15 D: 20 mg PO d 1,2,8,9,15,16,22,23 CRD (4 28-d cycles) C: 20 mg/m2 IV d 1-2 cycle 1; 36 mg/m2 IV once daily d 8-9,15-16 cycle 1; for all subsequent doses 36 mg/m2 IV once daily d 1-2,8-9,15-16 R: 25 mg PO daily d 1-21 D: 20 mg PO d 1,2,8,9,15,16,22,23 CCyD (4 28-d cycles) C: 36 mg/m2 IV once daily d 1-2,8-9,15-16 Cy: 300 mg/m2 PO d 1,8,15 D: 20 mg orally d 1,2,8,9,15,16,22,23 CRD (4 28-d cycles) C: 36 mg/m2 IV once daily d 1-2,8-9,15-16 R: 25 mg PO daily on days 1-21 D: 20 mg orally d 1,2,8,9,15,16,22,23 CRD (12 28-d cycles) C: 20 mg/m2 IV d 1-2 cycle 1; 36 mg/m2 IV once daily d 8-9,15-16 cycle 1; for all subsequent doses 36 mg/m2 IV once daily d 1-2,8-9,15-16 R: 25 mg PO daily on days 1-21 D: 20 mg PO d 1,2,8,9,15,16,22,23 T R A S P L A T R A D O M I Z A T I O R (until PD) R: 10 mg PO daily d1-21 CR (until PD) C: 36 mg/m2 IV once daily d 1-2,15-16 R: 10 mg PO daily d1-21 C, carfilzomib; Cy, cyclophosphamide; D, dexamethasone; R, lenalidomide; PO, orally; IV, intravenously; d, day; PD, progressive disease Clinicaltrials.gov number CT
11 Oral Proteasome inhibitor: Ixazomib Antitumor activity in preclinical xenograft models Four global phase 3 trials are ongoing: TOURMALIE MM1 (C16010): Ixazomib plus lenalidomide and dexamethasone in relapsed and/or refractory multiple myeloma TOURMALIE MM2 (C16014): Ixazomib plus lenalidomide and dexamethasone in newly diagnosed multiple myeloma TOURMALIE-AL1 (C16011): Ixazomib or physician s choice of treatment in relapsed or refractory AL amyloidosis TOURMALIE-MM3: Ixazomib maintenance therapy following autologous stem cell transplant in multiple myeloma
12 Ixaxomib Maintenance Best Response To Treatment In Phase 2 Patients 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% scr CR ncr VGPR PR MR SD Best response, (%) All patients, n=21 To maintenance CR+sCR+nCR 61 CR 33 scr 19 ncr 9 VGPR 10 CR+VGPR 71 PR 29 MR 0 0% Best response overall SD 0 10 (48%) patients improved their response during maintenance: 2 VGPR to ncr, 5 VGPR to CR, 1 VGPR to scr, and 2 CR to scr Kumar SK et al. Proc ASH 2014; Abstract 82.
13 Ixaxomib Maintenance Most common drug-related AEs During maintenance Any AE Skin and SC tissue disorders Diarrhea Fatigue ausea Peripheral neuropathies EC Constipation Insomnia Vomiting Dysgeusia Abdominal distension Malaise Muscle spasms Anemia Thrombocytopenia Hypokalemia Pain in extremity Headache During Patients, % EC, not elsewhere classified
14 C16019 (TOURMALIE MM-3): Phase 3 Study of Maintenance Post-ASCT Arm A: Ixazomib Cycles 1-4: Ixazomib (3.0 mg) po days 1, 8, 15 Cycles 5-26: Ixazomib (3.0 or 4.0 mg) po days 1, 8, 15 Randomization 652 patients 28-day cycles Arm B: Placebo Cycles 1-4: Matching placebo (3.0 mg) po days 1, 8, 15 Cycles 5-26: Matching placebo (3.0 or 4.0 mg) po days 1, 8, day cycles Inclusion Criteria: Symptomatic MM; Received standard of care induction therapy followed by single SCT within 12 months of diagnosis, w/o consolidation therapy; Documented response ( PR) to SCT, with no relapse; ECOG performance status 0-2 C16021 (TOURMALIE MM-4): Phase 3 Study of Oral Ixazomib Maintenance in Patients ot ASCT Eligible Arm A: Ixazomib Cycles 1-4: Ixazomib (3.0 mg) po days 1, 8, 15 Cycles 5-26: Ixazomib (3.0 or 4.0 mg) po days 1, 8, 15 Randomization 28-day cycles up to 26 cycles Inclusion Criteria: Symptomatic MM; Initial treatment for 6-12 months (± 2 wks) to best resp PR; ECOG performance status 0-2 Select Endpoints: Primary: PFS; Secondary: OS, ORR, TTP, 2 nd PFS Arm B: Placebo Cycles 1-4: Placebo (3.0 mg) po days 1, 8, 15 Cycles 5-26: Placebo (3.0 or 4.0 mg) po days 1, 8, day cycles up to 26 cycles
15 100% Lenalidomide maintenance RV-MM-PI-209 Best response to treatment (n=115) % 80% 70% 60% 50% 40% All patients, n=115 Best response, n (%) Overall CR+VGPR+PR 113 (98) CR 46 (40) VGPR 43 (37) PR 24 (21) 30% SD 2 (2) 20% 46 10% 26 0% Induction Overall CR VGPR PR SD 25 patients improved their response during lenalidomide maintenance: - 12 VGPR improved to CR - 13 PR improved to 5 VGPR and 8 CR Palumbo A, et al. Engl J Med Sep 4;371:
16 Lenalidomide maintenance RV-MM-PI-209 Grade 3-4 AEs during lenalidomide maintenance neutropenia thrombocytopenia anemia dermatologic infections endocrinologic 0% 5% 10% 15% 20% 25% Patients (%) Palumbo A, et al. Engl J Med Sep 4;371:
17 Continuous vs Fixed-Duration: PFS MRC Myeloma IX RVMM 209 Thalidomide maintenance: PFS Lenalidomide maintenance: PFS Median 41.9 months Median 15 months Median 23 months Morgan GJ, et al. Blood 2012;119:7 IFM Lenalidomide maintenance: PFS Median 21.6 months Len. maintenance o maintenance Palumbo A, et al. EJM. 2014;371:895 CALGB Lenalidomide maintenance: TTP HR 0.47; P<0.001 Median 41 months Median 53 months Median 23 months Median 26 months P<0.001 Attal M, et al. EJM 2012;366:1782 Holstein S, et al. ASCO 2015:8523
18 % of patients = 1218 Continuous vs Fixed-Duration Meta-analysis of 3 studies: 1218 patients 1-year Landmark analysis O S P F S P F S PFS1 PFS2 Ind. Maintenance Ind. Maintenance Median CT 32 mos CT Median 55 mos FDT 16 mos 75 FDT 40 mos = nd P F S HR 0.47, 95% CI , P < HR 0.61, 95% CI , P < Months Months CT, continuous therapy; FDT, fixed duration of therapy; PFS, progression-free survival; mos, months. Palumbo A, et al. JCO 2015 in Press
19 Conclusion Lenalidomide extensive efficacy/safety evidence Ixaxomib is under evaluation Limited value for IV drugs Monthly exposure with MoAb in the future
COMy Congress The case for IMids. Xavier Leleu. Hôpital la Milétrie, PRC, CHU, Poitiers, France
Xavier Leleu Hôpital la Milétrie, PRC, CHU, Poitiers, France The case for IMids COMy Congress 21 Disclosures Grants/research support: Amgen, Bristol-Myers Squibb, Celgene, Janssen, Millennium/Takeda, Novartis,
Novel Combination Therapies for Untreated Multiple Myeloma
Novel Combination Therapies for Untreated Multiple Myeloma Andrzej J. Jakubowiak, MD, PhD Director, Myeloma Program New York, NY, October 27, 201 Disclosures 2 Employee Consultant Major Stockholder Speakers
CME Information LEARNING OBJECTIVES
CME Information LEARNING OBJECTIVES Identify patients with MM who have undergone autologous stem cell transplant and would benefit from maintenance lenalidomide. Counsel older patients (age 65 or older)
To Maintain or Not to Maintain? Immunomodulators vs PIs Yes: Proteasome Inhibitors
To Maintain or Not to Maintain? Immunomodulators vs PIs Yes: Proteasome Inhibitors James Berenson, MD Institute for Myeloma and Bone Cancer Research West Hollywood, CA Financial Disclosures Takeda, Celgene
Initial Therapy For Transplant-Eligible Patients With Multiple Myeloma. Michele Cavo, MD University of Bologna Bologna, Italy
Initial Therapy For Transplant-Eligible Patients With Multiple Myeloma Michele Cavo, MD University of Bologna Bologna, Italy Treatment Paradigm for Autotransplant-Eligible Patients With Multiple Myeloma
Standard of care for patients with newly diagnosed multiple myeloma who are not eligible for a transplant
Standard of care for patients with newly diagnosed multiple myeloma who are not eligible for a transplant Pr Philippe Moreau University Hospital, Nantes, France MP: Standard of care until 2007 J Clin Oncol
TREATMENT FOR NON-TRANSPLANT ELIGIBLE MULTIPLE MYELOMA
TREATMENT FOR NON-TRANSPLANT ELIGIBLE MULTIPLE MYELOMA Ekarat Rattarittamrong, MD Division of Hematology Department of Internal Medicine Faculty of Medicine Chiang Mai University OUTLINE Overview of treatment
Treatment of elderly multiple myeloma patients
SAMO Interdisciplinary Workshop on Myeloma March 30 th -31 st 2012, Seehotel Hermitage, Lucerne Treatment of elderly multiple myeloma patients Federica Cavallo, MD, PhD Federica Cavallo, MD, PhD Division
Update on Multiple Myeloma Treatment
Update on Multiple Myeloma Treatment Professor Chng Wee Joo Director National University Cancer Institute of Singapore (NCIS) National University Health System (NUHS) Deputy Director Cancer Science Institute,
Consolidation and Maintenance therapy
University of Salamanca Consolidation and Maintenance therapy María-Victoria Mateos, MD, PhD University Hospital of Salamanca, Spain Disclosure form MVM has served as member of advisory boards or received
CREDIT DESIGNATION STATEMENT
CME Information LEARNING OBJECTIVES Integrate emerging research information on the use of proteasome inhibitors and immunomodulatory agents to individualize induction treatment recommendations and maintenance
Christine Chen Princess Margaret Cancer Centre September 2013
Christine Chen Princess Margaret Cancer Centre September 2013 Disclosures Research Support Celgene, Janssen, GSK Employee N/A Consultant N/A Major Stockholder Speakers Bureau/ Scientific Advisory Board
Role of consolidation therapy in Multiple Myeloma. Pieter Sonneveld. Erasmus MC Cancer Institute Rotterdam The Netherlands
Role of consolidation therapy in Multiple Myeloma Pieter Sonneveld Erasmus MC Cancer Institute Rotterdam The Netherlands Disclosures Research support : Amgen, Celgene, Janssen, Karyopharm Advisory Boards/Honoraria:
Multiple myeloma, 25 (45) years of progress. The IFM experience in patients treated with frontline ASCT. Philippe Moreau, Nantes
Multiple myeloma, 25 (45) years of progress The IFM experience in patients treated with frontline ASCT Philippe Moreau, Nantes Shibata T. Prolonged survival in a case of multiple myeloma treated with high
Terapia del mieloma. La terapia di prima linea nel paziente giovane. Elena Zamagni
Terapia del mieloma La terapia di prima linea nel paziente giovane Elena Zamagni Istituto di Ematologia ed Oncologia Medica Seràgnoli Università degli Studi di Bologna Newly diagnosed MM Candidate for
Novel treatment strategies for multiple myeloma: a focus on oral proteasome inhibitors
Novel treatment strategies for multiple myeloma: a focus on oral proteasome inhibitors Antonio Palumbo M.D. Takeda Pharmaceuticals International AG Introduction Multiple genetically-distinct subclones
Is autologous stem cell transplant the best consolidation after initial therapy?
Is autologous stem cell transplant the best consolidation after initial therapy? William Bensinger, MD Professor of Medicine, Division of Oncology University of Washington School of Medicine Director,
Maintenance therapy after autologous transplantation
Maintenance therapy after autologous transplantation Sonja Zweegman MD PhD Department of Hematology Amsterdam The Netherlands Disclosures Research funding from Celgene, Takeda and Janssen Participation
Myeloma update ASH 2014
Myeloma update ASH 2014 Updates in Newly Diagnosed Multiple Myeloma FIRST: effect of age on lenalidomide/dexamethasone vs MPT in transplantation-ineligible pts Phase III: MPT-T vs MPR-R in transplantation-ineligible
Progress in Multiple Myeloma
Progress in Multiple Myeloma Sundar Jagannath, MD Professor, New York Medical College Adjunct Professor, New York University St. Vincent s Comprehensive Cancer Center, NY Faculty Disclosure Advisory Board:
Multiple Myeloma: ASH 2008
Multiple Myeloma: ASH 2008 Steven Coutre, M.D. Associate Professor of Medicine Division of Hematology Stanford University School of Medicine About These Slides These slides accompany CCO s comprehensive
Curing Myeloma So Close and Yet So Far! Luciano J. Costa, MD, PhD Associate Professor of Medicine University of Alabama at Birmingham
Curing Myeloma So Close and Yet So Far! Luciano J. Costa, MD, PhD Associate Professor of Medicine University of Alabama at Birmingham What is cure after all? Getting rid of it? Stopping treatment without
How to Integrate the New Drugs into the Management of Multiple Myeloma
How to Integrate the New Drugs into the Management of Multiple Myeloma Carol Ann Huff, MD The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins NCCN.org For Clinicians NCCN.org/patients For Patients
To Maintain or Not to Maintain? Lymphoma and Myeloma 2015 Waldorf Astoria Hotel, New York
To Maintain or Not to Maintain? Lymphoma and Myeloma 2015 Waldorf Astoria Hotel, New York Sundar Jagannath Director, Multiple Myeloma Program Tisch Cancer Institute Mount Sinai Medical Center Maintenance
Unmet Medical Needs and Latest Multiple Myeloma Treatment
Unmet Medical Needs and Latest Multiple Myeloma Treatment Professor Chng Wee Joo Director National University Cancer Institute of Singapore (NCIS) National University Health System (NUHS) Deputy Director
Continuous Therapy as a Standard of Care CON. JL Harousseau Institut de Cancérologie de l Ouest Nantes Saint Herblain France
Continuous Therapy as a Standard of Care CON JL Harousseau Institut de Cancérologie de l Ouest Nantes Saint Herblain France 1 In France and in the IFM all debates 2 In France and in the IFM all debates
Induction Therapy: Have a Plan. Sagar Lonial, MD Professor, Winship Cancer Institute Director of Translational Research, B-cell Malignancy Program
Induction Therapy: Have a Plan Sagar Lonial, MD Professor, Winship Cancer Institute Director of Translational Research, B-cell Malignancy Program Topics When to treat? Smoldering vs Symptomatic Risk stratification
Multiple Myeloma Updates 2007
Multiple Myeloma Updates 2007 Brian Berryman, M.D. Multiple Myeloma Updates 2007 Goals for today: Understand the staging systems for myeloma Understand prognostic factors in myeloma Review updates from
Role of Maintenance and Consolidation Therapy in Multiple Myeloma: A Patient-centered Approach
Role of Maintenance and Consolidation Therapy in Multiple Myeloma: A Patient-centered Approach Jacob Laubach, MD Assistant Professor in Medicine Harvard Medical School Clinical Director of the Jerome Lipper
Il trattamento del Mieloma su stratificazione di rischio: è oggi possibile?
Il trattamento del Mieloma su stratificazione di rischio: è oggi possibile? Francesca Gay, MD Divisione Ematologia 1 AO Città della Salute e della Scienza, Torino, Italy Focus sul MM 2014 Cagliari, 30-31
Highlights from EHA Mieloma Multiplo
Highlights from EHA Mieloma Multiplo Michele Cavo Istituto di Ematologia L. e A. Seràgnoli Alma Mater Studiorum Università degli studi di Bologna Firenze, 22-23 Settembre 27 Myeloma XI TE pathway 7 R :
Consolidation and maintenance therapy for transplant eligible myeloma patients
Consolidation and maintenance therapy for transplant eligible myeloma patients Teeraya Puavilai, M.D. Division of Hematology, Department of Medicine Faculty of Medicine Ramathibodi Hospital Mahidol University
How I Treat Transplant Eligible Myeloma Patients
How I Treat Transplant Eligible Myeloma Patients Michele Cavo Seràgnoli Institute of Hematology, Bologna University School of Medicine, Italy Podcetrtek, Slovene, April 14 th, 2012 NEW TREATMENT PARADIGM
Multiple Myeloma: Induction, Consolidation and Maintenance Therapy
Multiple Myeloma: Induction, Consolidation and Maintenance Therapy James R. Berenson, MD Medical & Scientific Director Institute for Myeloma & Bone Cancer Research Los Angeles, CA Establish the Goals of
Treatment of elderly patients with multiple myeloma
Treatment of elderly patients with multiple myeloma Mario Boccadoro DIVISIONE UNIVERSITARIA DI EMATOLOGIA AZIENDA OSPEDALIERA SAN GIOVANNI TORINO, ITALY Improved survival in multiple myeloma and the impact
IMiDs (Immunomodulatory drugs) and Multiple Myeloma
www.comtecmed.com/comy comy@comtecmed.com IMiDs (Immunomodulatory drugs) and Multiple Myeloma Xavier Leleu Service des Maladies du Sang Hôpital Huriez, CHRU, Lille, France www.comtecmed.com/comy comy@comtecmed.com
Induction Therapy in Transplant Eligible MM 2 December Tontanai Numbenjapon, M.D.
Induction Therapy in Transplant Eligible MM 2 December 2017 Tontanai Numbenjapon, M.D. What we need from induction therapy in NDMM Depth of response: MRD-negative, scr, CR Longest response Acceptable toxicity
Approach to the Treatment of Newly Diagnosed Multiple Myeloma. S. Vincent Rajkumar Professor of Medicine Mayo Clinic
Approach to the Treatment of Newly Diagnosed Multiple Myeloma S. Vincent Rajkumar Professor of Medicine Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic College of
Management of Multiple
Management of Multiple Myeloma in the Elderly Xavier Leleu Service des Maladies du Sang Hôpital Huriez, CHRU, Lille, France INSERM U837, équipe 3 IRCL, CHRU, Lille, France IMPRT Institut de Médecine Prédictive
Myeloma and renal failure Future directions. Karthik Ramasamy
Myeloma and renal failure Future directions Karthik Ramasamy Overview Historical perspective & Background Drug interventions & trials OPTIMAL Trial Future directions Burden of disease Upto 40% of newly
MAINTENANCE AND CONTINUOUS THERAPY OF MYELOMA. Myeloma Day 11/18/2017 Aric Hall, MD Assistant Professor UW School of Medicine & Public Health
MAINTENANCE AND CONTINUOUS THERAPY OF MYELOMA Myeloma Day 11/18/2017 Aric Hall, MD Assistant Professor UW School of Medicine & Public Health Disclosures I have no significant conflicts of interest to disclose.
Management of Multiple Myeloma: The Changing Paradigm
Management of Multiple Myeloma: The Changing Paradigm High-Dose Chemotherapy and Stem Cell Transplantation Todd Zimmerman, MD University of Chicago Medical Center Case Presentation R.M. is a 64 year old
Daratumumab: Mechanism of Action
Phase 3 Randomized Controlled Study of Daratumumab, Bortezomib and Dexamethasone (D) vs Bortezomib and Dexamethasone () in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): CASTOR* Antonio
Multiple Myeloma Brian Berryman, M.D. March 8 th, 2014
Multiple Myeloma 2014 Brian Berryman, M.D. March 8 th, 2014 Kyle, R. A. et al. Blood 2008;111:2962-2972 Updates in Multiple Myeloma CCO Independent Conference Coverage of the 2013 Annual Meeting of
Managing Newly Diagnosed Multiple Myeloma
Managing Newly Diagnosed Multiple Myeloma 26 Jan 2018 Alfred Garfall, MD Assistant Professor of Medicine Diagnosis of Multiple Myeloma Traditional criteria: Monoclonal plasma cells + attributable CRAB
Michel Delforge Belgium. New treatment options for multiple myeloma
Michel Delforge Belgium New treatment options for multiple myeloma Progress in the treatment of MM over the past 40 years 1962 Prednisone + melphalan 1990s Supportive care 1999 First report on thalidomide
Methods: Studies included in the analysis
Efficacy and safety of long-term ixazomib maintenance therapy in patients with newly diagnosed multiple myeloma not undergoing transplant: An integrated analysis of four phase 1/2 studies Meletios A. Dimopoulos,
MYELOMA MAINTENANCE BEST PRACTICES:
MYELOMA MAINTENANCE BEST PRACTICES: POST THERAPY & POST TRANSPLANT Aric Hall, MD Assistant Professor University of Wisconsin Hospital and Clinics INTRODUCTION MYELOMA Clonal plasma cell malignancy leading
Debate: Is transplant a necessity or a choice? Focus on the necessity for CR and MRD. Answer: NO
Debate: Is transplant a necessity or a choice? Focus on the necessity for CR and MRD. Answer: NO Tomer M. Mark Department of Medicine, Division of Hematology / Oncology Weill-Cornell Medical College /
Current Management of Multiple Myeloma. December 2012 Kevin Song MD FRCPC Leukemia/BMT Program of B.C.
Current Management of Multiple Myeloma December 2012 Kevin Song MD FRCPC Leukemia/BMT Program of B.C. Disclosures Honoraria Speaker Celgene, Janssen, Novartis Celgene, Janssen Research Support Celgene
Timing of Transplant for Multiple Myeloma
Timing of Transplant for Multiple Myeloma Wenming CHEN Beijing Chaoyang Hospital Capital Medical University Multiple myeloma resrarch center of Beijing Initial Approach to Treatment of Myeloma Nontransplantation
Treatment Advances in Multiple Myeloma: Expert Perspectives on Translating Clinical Data to Practice
Treatment Advances in Multiple Myeloma: Expert Perspectives on Translating Clinical Data to Practice Friday, December 2, 2016 San Diego, California This program is supported by educational grants from
Treatment Strategies for Transplant-ineligible NDMM Patients
1 Treatment Strategies for Transplant-ineligible NDMM Patients Thierry Facon, MD Professor of Hematology Service des Maladies du Sang University of Lille Lille, France Multiple Myeloma affects primarily
Antibodies are a standard part of first relapse management in multiple myeloma (MM): Yes
Antibodies are a standard part of first relapse management in multiple myeloma (MM): Yes Ajay Nooka, MD MPH FACP Assistant Professor, Division of Bone Marrow Transplant Winship Cancer Institute, Emory
Post Transplant Maintenance- for everyone? Disclosures
Post Transplant Maintenance- for everyone? NO Because of limited survival data, not all patients require maintenance April 2012 Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Joseph Mikhael,
MULTIPLE MYELOMA. TREATMENT in 2017 MC. VEKEMANS
MULTIPLE MYELOMA TREATMENT in 2017 MC. VEKEMANS NATURAL HISTORY of MM WHO SHOULD BE TREATED? DEFINITION MGUS Smouldering Multiple Myeloma Symptomatic Multiple Myeloma Monoclonal component (blood and/or
Best of ASH 2017 DR. BRIAN DURIE. Brian GM Durie, MD Thursday, January 11, 2018
Best of ASH 2017 DR. BRIAN DURIE Brian GM Durie, MD Thursday, January 11, 2018 1 ASH Overview 2017 Total myeloma abstracts: 981 Important/Interesting: oral ~40 posters ~60 100 2 Which abstracts impact
UK MRA Myeloma XII Relapsed Intensive Study CI: Prof Gordon Cook
UK Myeloma Research Alliance Myeloma XII study (ACCoRD): Augmented Conditioning & Consolidation in Relapsed Disease UK MRA Myeloma XII Relapsed Intensive Study CI: Prof Gordon Cook Sponsor ID: Pending
Multiple Myeloma: Diagnosis and Primary Treatment
Multiple Myeloma: Diagnosis and Primary Treatment George Somlo, MD City of Hope Comprehensive Cancer Center NCCN.org For Clinicians NCCN.org/patients For Patients Educational Objectives Discuss considerations
Risk stratification in the older patient; what are our priorities?
Risk stratification in the older patient; what are our priorities? Sonja Zweegman MD PhD Amsterdam The Netherlands Negative impact of age on survival Meta-analysis of European trials (MP vs MPT, VMP vs
Transplant in MM patients: Early versus late. Mario Boccadoro. Barcelona
Transplant in MM patients: Early versus late Barcelona 8-9-2012 Mario Boccadoro DIVISIONE UNIVERSITARIA DI EMATOLOGIA AZIENDA OSPEDALIERA SAN GIOVANNI TORINO, ITALY Transplant in MM patients: Early versus
Novel Treatment Advances and Approaches in Management of Relapsed/Refractory Multiple Myeloma
Novel Treatment Advances and Approaches in Management of Relapsed/Refractory Multiple Myeloma Ravi Vij, MD MBA Professor of Medicine Washington University School of Medicine Section of Stem Cell Transplant
Bendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma
Bendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma Friedberg JW et al. Proc ASH 2009;Abstract 924. Introduction > Bendamustine (B)
Clinical Case Study Discussion: Maintenance in MM
www.comtecmed.com/comy comy@comtecmed.com Evangelos Terpos, MD, PhD National & Kapodistrian University of Athens, School of Medicine, Athens, Greece Clinical Case Study Discussion: Maintenance in MM Disclosure
Getting Clear Answers to Complex Treatment Challenges in Multiple Myeloma: Case Discussions
Getting Clear Answers to Complex Treatment Challenges in Multiple Myeloma: Case Discussions Friday, December 8, 2017 Atlanta, Georgia Friday Satellite Symposium preceding the 59th ASH Annual Meeting &
New Agents Beyond Brentuximab vedotin for Hodgkin Lymphoma. Stephen M. Ansell, MD, PhD Professor of Medicine Mayo Clinic
New Agents Beyond Brentuximab vedotin for Hodgkin Lymphoma Stephen M. Ansell, MD, PhD Professor of Medicine Mayo Clinic Disclosures for Stephen Ansell, MD, PhD In compliance with ACCME policy, Mayo Clinic
Choosing upfront and salvage therapy for myeloma in the ASEAN context
Choosing upfront and salvage therapy for myeloma in the ASEAN context Daryl Tan Consultant Department of Haematology Singapore General Hospital Adjunct Assistant Professor Duke-NUS Graduate Medical School
Oncology Highlights ASCO 2011 MULTIPLE MYELOMA
Oncology Highlights ASCO 211 MULTIPLE MYELOMA July 211 Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Joseph Mikhael, MD, MEd, FRCPC Staff Hematologist, Mayo Clinic Arizona Disclosures
Novel Therapies for the Treatment of Newly Diagnosed Multiple Myeloma
Novel Therapies for the Treatment of Newly Diagnosed Shaji K. Kumar, MD Professor of Medicine Mayo Clinic College of Medicine Consultant, Division of Hematology Medical Director, Cancer Clinical Research
Is Transplant a Necessity or a Choice: Focus on the necessity for CR and MRD
Is Transplant a Necessity or a Choice: Focus on the necessity for CR and MRD Ajai Chari, MD Associate Professor of Medicine Director of Clinical Research Multiple Myeloma Program Mount Sinai Medical Center
Abstract. Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY, USA; 2 Hospital-12-de-Octubre, Madrid, Spain; 3
Daratumumab, Carfilzomib, and Dexamethasone (D-Kd) in Lenalidomiderefractory Patients with Relapsed Multiple Myeloma (MM): Subgroup Analysis of MMY11 Chari A, 1* Martinez-Lopez J, 2 Mateos M-V, 3 Bladé
Living Well with Myeloma Teleconference Series Thursday, March 24 th :00 PM Pacific/5:00 PM Mountain 6:00 PM Central/7:00 PM Eastern
Living Well with Myeloma Teleconference Series Thursday, March 24 th 216 4: PM Pacific/5: PM Mountain 6: PM Central/7: PM Eastern Speakers Dr. Brian Durie, IMF Chairman Cedars Sinai Samuel Oschin Cancer
Induction Therapy & Stem Cell Transplantation for Myeloma
Induction Therapy & Stem Cell Transplantation for Myeloma William Bensinger, MD Professor of Medicine, Division of Oncology University of Washington School of Medicine Director, Autologous Stem Cell Transplant
Updates in Multiple Myeloma: 12 months in 10 minutes
Updates in Multiple Myeloma: 12 months in 10 minutes Aaron Rosenberg MD, MS Assistant Prof. Medicine UC Davis Comprehensive Cancer Center Division of Hematology and Oncology Outline Standard of care for
Meu paciente realizou um TACTH na 1a linha, e agora? Tandem, Manutenção, Consolidação? Marcelo C Pasquini, MD, MS Medical College of Wisconsin
Meu paciente realizou um TACTH na 1a linha, e agora? Tandem, Manutenção, Consolidação? Marcelo C Pasquini, MD, MS Medical College of Wisconsin Post Auto HCT Options for MM Maintenance Lenalidomide vs.
Upfront Therapy for Myeloma Tailoring Therapy across the Disease Spectrum
Upfront Therapy for Myeloma Tailoring Therapy across the Disease Spectrum S. Vincent Rajkumar Professor of Medicine Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic
Multiple Myeloma: Miami, FL Current Treatment Paradigms and Future Directions December 18, 2009
Welcome to Master Class for Oncologists Miami, FL December 18, 29 Session 5: 11: AM - 11:45 AM Multiple Myeloma: Current Treatment Paradigms and Future Directions Speaker: Kenneth C. Anderson, MD Chief,
Getting Clear Answers to Complex Treatment Challenges in Multiple Myeloma: Case Discussions
Getting Clear Answers to Complex Treatment Challenges in Multiple Myeloma: Case Discussions Friday, December 8, 2017 Atlanta, Georgia Friday Satellite Symposium preceding the 59th ASH Annual Meeting &
ClinicalTrials.gov Identifier: NCT
Efficacy of Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone Alone for Relapsed or Refractory Multiple Myeloma Among Patients With to 3 Prior Lines of Therapy Based on
LONDON CANCER NEWS DRUGS GROUP RAPID REVIEW
LONDON CANCER NEWS DRUGS GROUP RAPID REVIEW Bortezomib as first line induction prior to melphalan and autologous stem cell transplantation (ASCT) in untreated symptomatic multiple myeloma patients suitable
Highlights in multiple myeloma
3 CONGRESS HIGHLIGHTS Highlights in multiple myeloma P. Vlummens, MD SUMMARY Multiple myeloma (MM) remains a devastating disease, even in the era of novel agents. As such, the search for new treatment
Autologous Stem Cell Transplantation in Multiple Myeloma Optimal Frontline Therapy and Maintenance Therapy
Autologous Stem Cell Transplantation in Multiple Myeloma Optimal Frontline Therapy and Maintenance Therapy Donna E. Reece, M.D. Princess Margaret Hospital Toronto, ON CANADA 10 December 2011 ASCT in Myeloma..
Pomalidomide (CC4047) Plus Low-Dose Dexamethasone as Therapy for Relapsed Multiple Myeloma. Lacy MQ et al. J Clin Oncol 2009;27(30):
Pomalidomide (CC4047) Plus Low-Dose Dexamethasone as Therapy for Relapsed Multiple Myeloma Lacy MQ et al. J Clin Oncol 2009;27(30):5008-14. Introduction A curative therapy for multiple myeloma (MM) does
New IMWG Response Criteria
New IMWG Response Criteria Shaji Kumar, M.D. Professor of Medicine Division of Hematology Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic College of Medicine Mayo
Disclosures for Alessandra Larocca, MD
Disclosures for Alessandra Larocca, MD Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau Honoraria No relevant conflicts of interest to declare No relevant conflicts of interest
TREATING RELAPSED / REFRACTORY MYELOMA AT THE LEADING EDGE
TREATING RELAPSED / REFRACTORY MYELOMA AT THE LEADING EDGE PRESENTED BY: Pooja Chaukiyal MD Hematologist/Oncologist New York Oncology Hematology Albany, NY April 16, 2016 Background The prognosis for patients
VI. Autologous stem cell transplantation and maintenance therapy
Hematological Oncology Hematol Oncol 2013; 31 (Suppl. 1): 42 46 Published online in Wiley Online Library (wileyonlinelibrary.com).2066 Supplement Article VI. Autologous stem cell transplantation and maintenance
Disclosures. Consultancy, Research Funding and Speakers Bureau: Celgene Corporation, Millennium, Onyx, Cephalon
Pomalidomide With or Without Low-dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma: Outcomes in Patients Refractory to Lenalidomide and Bortezomib Ravi Vij 1, Paul G. Richardson
ClinicalTrials.gov Identifier: NCT
Efficacy of Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma Based on Prior Lines of Therapy: Updated Analysis of CASTOR Maria-Victoria
ASCO Analyst & Investor Webcast. June 1, 2018
ASCO Analyst & Investor Webcast June 1, 2018 June 1, 2018 NASDAQ: BLUE Forward Looking Statements These slides and the accompanying oral presentation contain forward-looking statements and information
COMy Congress A New Era of Advances in Myeloma. S. Vincent Rajkumar Professor of Medicine Mayo Clinic
A New Era of Advances in Myeloma S. Vincent Rajkumar Professor of Medicine Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic College of Medicine Mayo Clinic Comprehensive
Daratumumab: Mechanism of Action
An Open-label, Randomised, Phase 3 Study of Daratumumab, Lenalidomide, and Dexamethasone (D) Versus Lenalidomide and Dexamethasone () in Relapsed or Refractory Multiple Myeloma (RRMM): POLLUX* Meletios
Relapsed Myeloma Sequencing Treatments
Relapsed Myeloma Sequencing Treatments Noopur Raje, MD Director, Center for Multiple Myeloma MGH Cancer Center Professor of Medicine Harvard Medical School Disclosures Consultant /Advisory Board: Celgene,
Consolidation after Autologous Stem Cell Transplantion
Consolidation after Autologous Stem Cell Transplantion Joan Bladé Laura Rosiñol Department of Hematology Hospital Clínic de Barcelona Berlin, September 11 th 2011 Autologous Stem Cell Transplant in Younger
Phase I Study of Carfilzomib and Panobinostat for Patients with Relapsed and Refractory Myeloma: A Multicenter MMRC Clinical Trial
Phase I Study of Carfilzomib and Panobinostat for Patients with Relapsed and Refractory Myeloma: A Multicenter MMRC Clinical Trial Jonathan L. Kaufman, Todd Zimmerman, Cara A. Rosenbaum, Anuj Mahindra,
Multiple Myeloma What is New? Can we talk cure? Rafat Abonour, M.D.
Multiple Myeloma What is New? Can we talk cure? Rafat Abonour, M.D. Multiple Myeloma Facts Second most prevalent hematologic neoplasm Nearly 24, new cases diagnosed in the US per year and 11, worldwide
What New in Hematopoietic Stem Cell Transplantation? Joseph M. Tuscano, M.D. UCD Cancer Center
What New in Hematopoietic Stem Cell Transplantation? Joseph M. Tuscano, M.D. UCD Cancer Center 1 JOSEPH TUSCNO, MD WHAT S NEW IN HEMATOPOEITIC STEM CELL TRANSPLANTATION? RELEVANT FINANCIAL RELATIONSHIPS
Phase 1 Study of ARRY-520 and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
Phase 1 Study of ARRY-520 and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Jatin J Shah, MD, Sheeba Thomas, MD, Donna Weber, MD, Michael Wang, MD, Raymond Alexanian, MD, Robert
Long-term ixazomib maintenance is tolerable and improves depth of response following ixazomiblenalidomide-dexamethasone
Long-term ixazomib maintenance is tolerable and improves depth of response following ixazomiblenalidomide-dexamethasone induction in patients with previously untreated multiple myeloma (MM): Phase 2 study
Stem Cell Transplant for Myeloma: The New Landscape
Stem Cell Transplant for Myeloma: The New Landscape Sergio A. Giralt, MD Chief, Adult Bone Marrow Transplant Service Division of Hematologic Oncology Department of Medicine Memorial Sloan-Kettering Cancer